Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
563 stopped studies mapped to Malignant Pancreatic Neoplasm and descendants · 93% state a reason
Over the 563 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and… | Phase 1 | withdrawn | Apr 24, 2019 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT00429858 | Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer | Phase 2 | terminated | Feb 1, 2007 | Andrew Ko | Study accrual rate is very slow, it was mandated by NCI to be terminated. | Enrollment / accrual |
| NCT03038477 | A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and… | Phase 2 | withdrawn | Jan 31, 2017 | University of Colorado, Denver | Cancelled by PI | Other (stated, no rule matched) |
| NCT03600623 | Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for… | Early Phase 1 | terminated | Jul 26, 2018 | University of Alabama at Birmingham | PI left the institution; no further accruals | Investigator |
| NCT03469258 | Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for… | Phase 2 | terminated | Mar 19, 2018 | Dana-Farber Cancer Institute | Sponsorship for trial was halted after company acquisition | Sponsor / business decision |
| NCT00882765 | Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | Phase 2 | withdrawn | Apr 16, 2009 | Jonsson Comprehensive Cancer Center | Study has been closed due to no accrual. | Enrollment / accrual |
| NCT02333409 | Acupuncture for Pain Control in Patients With Inoperable Pancreatic Cancer | N/A | terminated | Jan 7, 2015 | Chinese University of Hong Kong | Expertise resigned | Other (stated, no rule matched) |
| NCT03890198 | A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and… | Early Phase 1 | terminated | Mar 26, 2019 | First Affiliated Hospital Xi'an Jiaotong University | the Preliminary data, progress of this study and the adjustment of the pipeline and strategy . | Sponsor / business decision |
| NCT01092689 | The Role of Meat-borne Carcinogens in Pancreatic Cancer | Phase 1 | withdrawn | Mar 25, 2010 | University of Minnesota | Needed New IND per FDA | Other (stated, no rule matched) |
| NCT03891979 | Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in… | Phase 4 | withdrawn | Mar 27, 2019 | NYU Langone Health | Suspended due to Primary Investigator's decision | Investigator |
| NCT00614601 | Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer | Phase 2 | terminated | Feb 13, 2008 | NewLink Genetics Corporation | Sponsor proceeded with a phase III study for same indication. | Other (stated, no rule matched) |
| NCT00739609 | IDO Inhibitor Study for Relapsed or Refractory Solid Tumors(D-1MT) | Phase 1 | terminated | Aug 22, 2008 | NewLink Genetics Corporation | Lack of enrollment. | Enrollment / accrual |
| NCT01836432 | Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic…(PILLAR) | Phase 3 | terminated | Apr 19, 2013 | NewLink Genetics Corporation | Company decision | Sponsor / business decision |
| NCT02405585 | Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer | Phase 2 | terminated | Apr 1, 2015 | NewLink Genetics Corporation | not stated | Not stated |
| NCT02682082 | EUS Guided Neurolysis Celiac Block w/wo Bupivacaine in Patient Being Treated Palliatively…(EUS-CPN) | N/A | terminated | Feb 15, 2016 | Centre hospitalier de l'Université de Montréal (CHUM) | Closed by CHUM REB for incomplete documentation of research activities. | Other (stated, no rule matched) |
| NCT03286062 | VM110 in Detection of Microscopic Tumors: A Phase I Study | Phase 1 | terminated | Sep 18, 2017 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT01333124 | Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma | Phase 2 | terminated | Apr 11, 2011 | National Cancer Center, Korea | Recruitment delay | Enrollment / accrual |
| NCT03531125 | Gene Expression in Pancreatic Cancer(NEOPANC-01) | — | terminated | May 21, 2018 | University of Oxford | Study was closed early due to low numbers of evaluable patients | Other (stated, no rule matched) |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | Phase 1 / Phase 2 | withdrawn | Mar 21, 2016 | Zhi Yang | Reform CAR structure due to safety consideration | Safety / toxicity |
| NCT04058964 | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | Phase 2 | withdrawn | Aug 16, 2019 | M.D. Anderson Cancer Center | Study withdrawn by supporter | Other (stated, no rule matched) |
| NCT03277209 | To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on… | Phase 1 | terminated | Sep 8, 2017 | Weill Medical College of Cornell University | terminated due to slow accrual | Enrollment / accrual |
| NCT02926040 | Quality of Life After in Situ IRE in Locally Advanced Pancreatic Cancer(IRE Qol) | — | terminated | Oct 6, 2016 | Insel Gruppe AG, University Hospital Bern | PI left hospital | Investigator |
| NCT02952859 | Impact of Margin-accentuation IRE in Pancreatic Cancer(IRE Marg) | — | terminated | Nov 2, 2016 | Insel Gruppe AG, University Hospital Bern | PI left hospital | Investigator |
| NCT03069599 | Immune Response After Pancreatic Cancer Treatment(IRE Immuno) | — | terminated | Mar 3, 2017 | Insel Gruppe AG, University Hospital Bern | PI left hospital | Investigator |
| NCT03471468 | Kinetics of Microparticles Under Chemotherapy in Patients With Gastric or Pancreatic…(DOMICA) | N/A | terminated | Mar 20, 2018 | Poitiers University Hospital | Low recruitment | Enrollment / accrual |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients… | Phase 1 | terminated | Oct 15, 2015 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT04134468 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | Phase 2 | withdrawn | Oct 22, 2019 | Abramson Cancer Center at Penn Medicine | Halozyme halted development of PEGPH20 following Phase 3 failure. | Other (stated, no rule matched) |
| NCT02743975 | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma(PENGUIN) | Phase 1 / Phase 2 | terminated | Apr 19, 2016 | University Medical Center Groningen | Insufficient tumor-to-background ratios in the first three dose groups | Other (stated, no rule matched) |
| NCT02921646 | Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to…(EnergiePancrea) | N/A | terminated | Oct 3, 2016 | Center Eugene Marquis | Protocol is not adapted to cancer pancreas disease as progression is very fast and patients stopped… | Other (stated, no rule matched) |
| NCT03865563 | Selective Transvenous Chemoembolization of Primary Pancreatic Tumors | Phase 1 | withdrawn | Mar 7, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | We need to make significant adjustments to proposed drug and its delivery method | Other (stated, no rule matched) |
| NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for… | Phase 1 / Phase 2 | terminated | Sep 12, 2011 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Study was terminated due to cease in manufacturing of study drug. | Drug supply |
| NCT00394602 | Chemoradiation-Induced Nausea and Emesis: Quality of Life | — | terminated | Nov 1, 2006 | M.D. Anderson Cancer Center | Requested by PI during yearly Continuing Review | Other (stated, no rule matched) |
| NCT02465983 | Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer | Phase 1 | terminated | Jun 9, 2015 | University of Pennsylvania | Lack of efficacy and funding to continue investigation | Efficacy / futility |
| NCT03300843 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients… | Phase 2 | terminated | Oct 4, 2017 | National Cancer Institute (NCI) | slow accrual | Enrollment / accrual |
| NCT01240304 | A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation… | Phase 2 | terminated | Nov 15, 2010 | University of Arkansas | no subjects enrolled | Enrollment / accrual |
| NCT00728000 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic… | Phase 2 | withdrawn | Aug 5, 2008 | University of Cincinnati | study withdrawn due to lack of enrollment | Enrollment / accrual |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced…(LAPC-BC-819) | Phase 2 | terminated | Aug 10, 2011 | Anchiano Therapeutics Israel Ltd. | Due to Sponsor's decision, only 12 patients were randomized \& completed study. | Sponsor / business decision |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | Phase 2 | terminated | Dec 28, 2006 | National Cancer Institute (NCI) | Study was terminated due to poor accrual | Enrollment / accrual |
| NCT04130399 | Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and… | Phase 2 | withdrawn | Oct 17, 2019 | Indiana University | Study is being abandoned. | Other (stated, no rule matched) |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | Phase 1 / Phase 2 | terminated | Apr 24, 2012 | National Cancer Institute (NCI) | Study terminated due to slow/insufficient accrual. | Enrollment / accrual |
| NCT02166190 | RFA RCT for Pancreatic or Bile Duct Cancer(RFARCT) | N/A | terminated | Jun 18, 2014 | Weill Medical College of Cornell University | Enrollment was feasibly not going to be reached. | Enrollment / accrual |
| NCT01524575 | Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low… | Phase 2 | withdrawn | Feb 2, 2012 | University of Hawaii | the trial was never opened and then withdrawn permanently | Other (stated, no rule matched) |
| NCT02449967 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for… | Phase 1 / Phase 2 | withdrawn | May 21, 2015 | Fuda Cancer Hospital, Guangzhou | not stated | Not stated |
| NCT02885727 | Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post…(Panc-Durval+RT) | Phase 2 | withdrawn | Aug 31, 2016 | University of Maryland, Baltimore | Funding issues caused the study to not be opened the at local IRB | Funding |
| NCT00414570 | An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients… | Early Phase 1 | terminated | Dec 21, 2006 | AHS Cancer Control Alberta | Retirement of former Qualified Investigator and lack of resources to complete study | Investigator |
| NCT02352831 | Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | terminated | Feb 2, 2015 | Washington University School of Medicine | Insufficient funding and drug supply from manufacturer | Drug supply |
| NCT02570711 | Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects… | Phase 2 | terminated | Oct 7, 2015 | Acerta Pharma BV | Sponsor Decision | Sponsor / business decision |
| NCT03481920 | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic… | Early Phase 1 | terminated | Mar 29, 2018 | PH Research, S.L. | Stopped Enrollment | Enrollment / accrual |
| NCT02707328 | Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With… | Phase 1 | terminated | Mar 14, 2016 | The Cooper Health System | Closed after being on administrative hold | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 28, 2020source: clinicaltrials